These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 26056795

  • 1. Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
    Kalra M, Heath JA, Kellie SJ, Dalla Pozza L, Stevens MM, Swamy S, McCowage GB.
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):e341-6. PubMed ID: 26056795
    [Abstract] [Full Text] [Related]

  • 2. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
    Packer RJ, Jakacki R, Horn M, Rood B, Vezina G, MacDonald T, Fisher MJ, Cohen B.
    Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
    Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE.
    Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
    [Abstract] [Full Text] [Related]

  • 4. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
    Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Capelle F, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Desjardins A, Xuan KH, Chauffert B.
    Rev Neurol (Paris); 2008 Jan; 164(6-7):588-94. PubMed ID: 18565358
    [Abstract] [Full Text] [Related]

  • 5. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U.
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [Abstract] [Full Text] [Related]

  • 6. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J.
    Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
    [Abstract] [Full Text] [Related]

  • 7. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
    Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M, Lassen U.
    Acta Oncol; 2009 Sep; 48(1):52-8. PubMed ID: 19031176
    [Abstract] [Full Text] [Related]

  • 8. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
    Bokstein F, Shpigel S, Blumenthal DT.
    Cancer; 2008 May 15; 112(10):2267-73. PubMed ID: 18327820
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
    Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ.
    Pediatr Blood Cancer; 2013 May 15; 60(5):776-82. PubMed ID: 22976922
    [Abstract] [Full Text] [Related]

  • 10. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
    de Marcellus C, Tauziède-Espariat A, Cuinet A, Pasqualini C, Robert MP, Beccaria K, Puget S, Boddaert N, Figarella-Branger D, De Carli E, Bourdeaut F, Leblond P, Fouyssac F, Andre N, Bertozzi AI, Butel T, Dufour C, Valteau-Couanet D, Varlet P, Grill J.
    J Neurooncol; 2022 Apr 15; 157(2):355-364. PubMed ID: 35239111
    [Abstract] [Full Text] [Related]

  • 11. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
    Gil MJ, de Las Peñas R, Reynés G, Balañá C, Peréz-Segura P, García-Velasco A, Mesia C, Gallego O, Fernández-Chacón C, Martínez-García M, Herrero A, Andrés R, Benavides M, Quintanar T, Pérez-Martin X.
    Anticancer Drugs; 2012 Jul 15; 23(6):659-65. PubMed ID: 22634799
    [Abstract] [Full Text] [Related]

  • 12. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
    Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE.
    J Clin Oncol; 2010 Jun 20; 28(18):3069-75. PubMed ID: 20479404
    [Abstract] [Full Text] [Related]

  • 13. Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.
    Roux C, Revon-Rivière G, Gentet JC, Verschuur A, Scavarda D, Saultier P, Appay R, Padovani L, André N.
    J Pediatr Hematol Oncol; 2021 Jul 01; 43(5):e630-e634. PubMed ID: 33235152
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Okada K, Yamasaki K, Tanaka C, Fujisaki H, Osugi Y, Hara J.
    Jpn J Clin Oncol; 2013 Nov 01; 43(11):1073-9. PubMed ID: 24002900
    [Abstract] [Full Text] [Related]

  • 15. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS, Khanna PC, Tumblin M, Yeh-Nayre L, Milburn M, Elster JD, Crawford JR.
    Pediatr Blood Cancer; 2018 Sep 01; 65(9):e27234. PubMed ID: 29750399
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS.
    Clin Cancer Res; 2007 Feb 15; 13(4):1253-9. PubMed ID: 17317837
    [Abstract] [Full Text] [Related]

  • 17. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
    Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ.
    Clin Cancer Res; 2008 Nov 01; 14(21):7068-73. PubMed ID: 18981004
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
    Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S.
    J Clin Oncol; 2012 Apr 20; 30(12):1358-63. PubMed ID: 22393086
    [Abstract] [Full Text] [Related]

  • 19. Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?
    Heng MA, Padovani L, Dory-Lautrec P, Gentet JC, Verschuur A, Pasquier E, Figarella-Branger D, Scavarda D, André N.
    Cancer Med; 2016 Jul 20; 5(7):1542-5. PubMed ID: 27037940
    [Abstract] [Full Text] [Related]

  • 20. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.
    Couec ML, André N, Thebaud E, Minckes O, Rialland X, Corradini N, Aerts I, Marec Bérard P, Bourdeaut F, Leblond P, Comité Pharmacologie of the SFCE.
    Pediatr Blood Cancer; 2012 Jul 15; 59(1):34-8. PubMed ID: 22287258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.